Financial Performance - AEON Biopharma reported a net income of $2.083 million for Q4 2024, compared to a net loss of $26.241 million in Q4 2023[17]. - Research and development expenses for the year 2024 were $14.181 million, compared to $13.243 million in 2023, reflecting an increase of about 7.1%[17]. - The company’s accumulated deficit improved from $(473.602) million in 2023 to $(431.597) million in 2024, a reduction of approximately 8.9%[15]. Capital and Funding - The company closed a public offering on January 7, 2025, raising gross proceeds of $20.0 million, which will fund operations through 2025[5][6]. - Approximately 89% of the Series B warrants from the public offering have been exercised as of March 21, 2025[6]. Assets and Liabilities - Total current assets decreased from $6.222 million in 2023 to $1.590 million in 2024, a decline of approximately 74.5%[15]. - Current liabilities increased from $13.049 million in 2023 to $14.149 million in 2024, an increase of about 8.4%[15]. - The total liabilities decreased significantly from $159.889 million in 2023 to $31.711 million in 2024, a reduction of approximately 80.2%[15]. Regulatory and Development Activities - AEON is pursuing a 351(k) regulatory pathway for ABP-450, with primary analytical studies initiated in Q4 2024[4][2]. - The company plans to hold a Biosimilar Biological Product Development Type 2a meeting with the FDA in the second half of 2025[4]. Corporate Changes - The merger resulted in the historical financial statements of AEON Biopharma Sub, Inc. becoming the historical financial statements of the combined Company[19]. - The financial statements reflect the Successor periods for the three months ended December 31, 2024, and December 31, 2023, as well as the year ended December 31, 2024[21]. - A reverse stock split at a ratio of 1-for-72 was effectuated on February 24, 2025, combining 72 pre-split shares into one new share of Common Stock[22].
AEON Biopharma(AEON) - 2024 Q4 - Annual Results